Drug Approved to Treat DMD Gets More Expensive
A new drug to treat Duchenne muscular dystrophy (DMD) has been around for decades in Europe, but will come to the market in the United States with a much bigger price tag. According to The Wall Street Journal, Marathon Pharmaceuticals LLC will bring deflazacort to the United States for $89,000 a year. The corticosteroid was approved Thursday to treat DMD. The drug isn’t a cure, however; instead, it improves muscle strength for boys affected by the disease. Americans have been importing deflazacort from the United Kingdom at a much lower price. The article highlights one mother who pays about $1600 annually.
Why Drug Price Hikes Can Be Necessary
The list price of deflazacort is a 6000% price increase over the price in Europe or Canada. However, Matthew Herper at Forbes explains why this price hike was necessary: because deflazacort had never been approved in the United States, Marathon had to get it approved, which meant conducting 17 clinical and preclinical trials. In the end, the high cost of the drug is necessary to pay for the cost of getting FDA approval and still making a profit.
The ACA’s Taxes
The Associated Press took a look at the taxes imposed by the Affordable Care Act that will bring in about $1.1 trillion in revenue over 10 years. For instance, the 3.8% tax on investment income over a certain threshold would bring in $223 billion in revenue. Overall, there are more than 10 individual taxes listed out by the AP that have helped pay for expanding health coverage. However, Republican efforts to replace or even alter the law could significantly affect this estimated revenue over the next decade.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
What We’re Reading: Affordable Home Care; Mycoplasma Infections Rise; Opioid Crisis Settlement
December 4th 2023Families struggle to find affordable, reliable home health aides; reports of increased pediatric pneumonia cases; legal battle ensues over Purdue Pharma’s bankruptcy settlement.
Read More
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
New Data Update Myasthenia Gravis Outcomes for Patients in Australia
December 3rd 2023Patients living with myasthenia gravis in Australia were surveyed their demographic information, clinical features of the autoimmune disease, adverse effects from treatment, and quality of life. Outcomes were compared against 2011 data from Australia and 2019 data from the United States.
Read More
NK Cell Therapy SNK01 Improves Cognitive Function in Alzheimer Disease for up to 11 Weeks
December 3rd 2023Among 10 patients evaluated, compared with their baseline at 1 week after receiving their final dose in the trial, 30% demonstrated clinical improvement on the Alzheimer’s disease composite score.
Read More